A review of 36 cytotoxic agents used singly in over 1,900 patients with renal cancer between 1983 and 1988 finds marginal antitumor activity, less than 5-10%. The future role of monoclonal antibodies for therapy of this disease may offer some hope with the recent description of rather specific phenotypic expression, URO 10+/URO 8+, suggesting the cell origin of most renal tumors from the distal portion of the proximal tubule.
No takes yet. Share an insight, caveat, or question.
Yagoda et al. (2010) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: